Skip to main content
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. — Investor Relations & Filings

Ticker · VIR ISIN · US92764N1028 US Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2021-10-20 Director's Dealing
Country US United States of America
Listing US VIR

About Vir Biotechnology, Inc.

https://www.vir.bio/

Vir Biotechnology, Inc. is a clinical-stage immunology company that leverages the immune system to treat and prevent serious infectious diseases and other conditions. The company's pipeline is built on two primary technology platforms: a next-generation antibody platform for identifying and optimizing therapeutic candidates, and the PRO-XTEN® protease-releasable masking technology for applications in oncology. Vir's main therapeutic area is infectious diseases, featuring a leading program for chronic hepatitis delta, and is complemented by strategic programs in oncology. The company has demonstrated its capabilities by developing antibody-based medicines for significant health challenges, including COVID-19 and Ebola.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-10-20 English
FORM 4 SUBMISSION
Director's Dealing
2021-10-08 English
FORM 4 SUBMISSION
Director's Dealing
2021-10-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content focuses on an update regarding global access to a COVID-19 treatment (sotrovimab) and agreements for its sale. There are no financial statements, detailed financial performance data, or comprehensive management discussion. The document is relatively short (4401 characters) and serves as an announcement of a business update rather than a full financial report or earnings release. It does not fit into categories like Annual Report, Earnings Release, or Interim Report. It is not a regulatory certification or officer attestation. The nature of the content is a general regulatory announcement about a business development. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-09-29 English
FORM 4 SUBMISSION
Director's Dealing
2021-09-29 English
FORM 4 SUBMISSION
Director's Dealing
2021-09-24 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.